2C-T-2

2C-T-2 (2,5-dimethoxy-4-ethylthiophenethylamine) is a psychedelic phenethylamine of the 2C-T (thio) subfamily, first synthesized by Alexander Shulgin and documented in PiHKAL (1991). It is the 4-ethylthio analog of 2C-T-7 and, like its siblings in the thio-phenethylamine family, carries a documented history of serious adverse events and fatalities that demand unambiguous safety emphasis.

At active doses (12–25 mg), 2C-T-2 produces a psychedelic experience of 6–8 hours characterized by visual phenomena, sensory enhancement, and — in some accounts — an introspective, emotionally open quality. Shulgin documented positive experiences with the compound and rated it favorably. However, the post-PiHKAL history of 2C-T-2 is substantially defined by serious adverse events and deaths reported in the early 2000s, which established the 2C-T family as carrying meaningfully higher risk than the non-thio 2C compounds.

The mechanism underlying the toxicity of 2C-T compounds is not fully characterized, but interaction with monoamine oxidase enzymes is implicated. The sulfur-containing substituent appears to create a substrate interaction with MAO that can produce unpredictable toxic effects, particularly in combination with other serotonergic substances. The harm reduction community consensus on 2C-T-2 is unambiguous: the risk/benefit profile, given the availability of safer psychedelic alternatives, does not support its use.